Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy

Covering: up to 2020 As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could...

Full description

Saved in:
Bibliographic Details
Published inNatural product reports Vol. 38; no. 3; pp. 47 - 488
Main Authors Zhao, Wei, Cong, Ying, Li, Hong-Mei, Li, Shengying, Shen, Yuemao, Qi, Qingsheng, Zhang, Youming, Li, Yue-Zhong, Tang, Ya-Jie
Format Journal Article
LanguageEnglish
Published England Royal Society of Chemistry 01.03.2021
Subjects
Anticancer properties
antineoplastic activity
Antineoplastic Agents - therapeutic use
Antitumor activity
bioactive compounds
Bioavailability
Biocompatibility
Cancer therapies
cancer therapy
Cell cycle
Central nervous system
Chemotherapy
Coronaviruses
COVID-19
COVID-19 infection
Cytokine storm
Cytokines
Deoxyribonucleic acid
DNA
DNA damage
DNA topoisomerase (ATP-hydrolysing)
Drug Design
Drug development
Drug resistance
drug therapy
Drugs
Etoposide
Growth factors
Health services
Herbal medicine
herbal medicines
Humans
Insulin
insulin-like growth factor I receptor
Lung cancer
lung neoplasms
Neoplasms - drug therapy
Podophyllotoxin
Podophyllotoxin - therapeutic use
Podophyllum
RNA
Small cell lung carcinoma
Teniposide
testes
Testicular cancer
Toxicity
Tubulin
Viral diseases
Online AccessGet full text

Cover

Abstract Covering: up to 2020 As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could arrest the cell cycle, block the transitorily generated DNA/RNA breaks, and blunt the growth-stimulation by targeting topoisomerase II, tubulin, or insulin-like growth factor 1 receptor. Since 1983, etoposide (VP-16) is being used in frontline cancer therapy against various cancer types, such as small cell lung cancer and testicular cancer. Surprisingly, VP-16 (ClinicalTrials NTC04356690) was also redeveloped to treat the cytokine storm in coronavirus disease 2019 (COVID-19) in phase II in April 2020. The treatment aims at dampening the cytokine storm and is based on etoposide in the case of central nervous system. However, the initial version of PTOX was far from perfect. Almost all podophyllotoxin derivatives, including the FDA-approved drugs VP-16 and teniposide, were seriously limited in clinical therapy due to systemic toxicity, drug resistance, and low bioavailability. To meet this challenge, scientists have devoted continuous efforts to discover new candidate drugs and have developed drug strategies. This review focuses on the current clinical treatment of PTOXs and the prospective analysis for improving druggability in the rational design of new generation PTOX-derived drugs. Natural product podophyllotoxin exhibited superior broad spectrum antitumor and antiviral activity. Over past 30 years, scientists devoted continuous efforts to develop druggability strategies and discover new podophyllotoxin-derived drugs.
AbstractList As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could arrest the cell cycle, block the transitorily generated DNA/RNA breaks, and blunt the growth-stimulation by targeting topoisomerase II, tubulin, or insulin-like growth factor 1 receptor. Since 1983, etoposide (VP-16) is being used in frontline cancer therapy against various cancer types, such as small cell lung cancer and testicular cancer. Surprisingly, VP-16 (ClinicalTrials NTC04356690) was also redeveloped to treat the cytokine storm in coronavirus disease 2019 (COVID-19) in phase II in April 2020. The treatment aims at dampening the cytokine storm and is based on etoposide in the case of central nervous system. However, the initial version of PTOX was far from perfect. Almost all podophyllotoxin derivatives, including the FDA-approved drugs VP-16 and teniposide, were seriously limited in clinical therapy due to systemic toxicity, drug resistance, and low bioavailability. To meet this challenge, scientists have devoted continuous efforts to discover new candidate drugs and have developed drug strategies. This review focuses on the current clinical treatment of PTOXs and the prospective analysis for improving druggability in the rational design of new generation PTOX-derived drugs.
Covering: up to 2020As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could arrest the cell cycle, block the transitorily generated DNA/RNA breaks, and blunt the growth-stimulation by targeting topoisomerase II, tubulin, or insulin-like growth factor 1 receptor. Since 1983, etoposide (VP-16) is being used in frontline cancer therapy against various cancer types, such as small cell lung cancer and testicular cancer. Surprisingly, VP-16 (ClinicalTrials NTC04356690) was also redeveloped to treat the cytokine storm in coronavirus disease 2019 (COVID-19) in phase II in April 2020. The treatment aims at dampening the cytokine storm and is based on etoposide in the case of central nervous system. However, the initial version of PTOX was far from perfect. Almost all podophyllotoxin derivatives, including the FDA-approved drugs VP-16 and teniposide, were seriously limited in clinical therapy due to systemic toxicity, drug resistance, and low bioavailability. To meet this challenge, scientists have devoted continuous efforts to discover new candidate drugs and have developed drug strategies. This review focuses on the current clinical treatment of PTOXs and the prospective analysis for improving druggability in the rational design of new generation PTOX-derived drugs.
Covering: up to 2020As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could arrest the cell cycle, block the transitorily generated DNA/RNA breaks, and blunt the growth-stimulation by targeting topoisomerase II, tubulin, or insulin-like growth factor 1 receptor. Since 1983, etoposide (VP-16) is being used in frontline cancer therapy against various cancer types, such as small cell lung cancer and testicular cancer. Surprisingly, VP-16 (ClinicalTrials NTC04356690) was also redeveloped to treat the cytokine storm in coronavirus disease 2019 (COVID-19) in phase II in April 2020. The treatment aims at dampening the cytokine storm and is based on etoposide in the case of central nervous system. However, the initial version of PTOX was far from perfect. Almost all podophyllotoxin derivatives, including the FDA-approved drugs VP-16 and teniposide, were seriously limited in clinical therapy due to systemic toxicity, drug resistance, and low bioavailability. To meet this challenge, scientists have devoted continuous efforts to discover new candidate drugs and have developed drug strategies. This review focuses on the current clinical treatment of PTOXs and the prospective analysis for improving druggability in the rational design of new generation PTOX-derived drugs.Covering: up to 2020As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could arrest the cell cycle, block the transitorily generated DNA/RNA breaks, and blunt the growth-stimulation by targeting topoisomerase II, tubulin, or insulin-like growth factor 1 receptor. Since 1983, etoposide (VP-16) is being used in frontline cancer therapy against various cancer types, such as small cell lung cancer and testicular cancer. Surprisingly, VP-16 (ClinicalTrials NTC04356690) was also redeveloped to treat the cytokine storm in coronavirus disease 2019 (COVID-19) in phase II in April 2020. The treatment aims at dampening the cytokine storm and is based on etoposide in the case of central nervous system. However, the initial version of PTOX was far from perfect. Almost all podophyllotoxin derivatives, including the FDA-approved drugs VP-16 and teniposide, were seriously limited in clinical therapy due to systemic toxicity, drug resistance, and low bioavailability. To meet this challenge, scientists have devoted continuous efforts to discover new candidate drugs and have developed drug strategies. This review focuses on the current clinical treatment of PTOXs and the prospective analysis for improving druggability in the rational design of new generation PTOX-derived drugs.
Covering: up to 2020 As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could arrest the cell cycle, block the transitorily generated DNA/RNA breaks, and blunt the growth-stimulation by targeting topoisomerase II, tubulin, or insulin-like growth factor 1 receptor. Since 1983, etoposide (VP-16) is being used in frontline cancer therapy against various cancer types, such as small cell lung cancer and testicular cancer. Surprisingly, VP-16 (ClinicalTrials NTC04356690) was also redeveloped to treat the cytokine storm in coronavirus disease 2019 (COVID-19) in phase II in April 2020. The treatment aims at dampening the cytokine storm and is based on etoposide in the case of central nervous system. However, the initial version of PTOX was far from perfect. Almost all podophyllotoxin derivatives, including the FDA-approved drugs VP-16 and teniposide, were seriously limited in clinical therapy due to systemic toxicity, drug resistance, and low bioavailability. To meet this challenge, scientists have devoted continuous efforts to discover new candidate drugs and have developed drug strategies. This review focuses on the current clinical treatment of PTOXs and the prospective analysis for improving druggability in the rational design of new generation PTOX-derived drugs. Natural product podophyllotoxin exhibited superior broad spectrum antitumor and antiviral activity. Over past 30 years, scientists devoted continuous efforts to develop druggability strategies and discover new podophyllotoxin-derived drugs.
Covering: up to 2020 As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could arrest the cell cycle, block the transitorily generated DNA/RNA breaks, and blunt the growth-stimulation by targeting topoisomerase II, tubulin, or insulin-like growth factor 1 receptor. Since 1983, etoposide (VP-16) is being used in frontline cancer therapy against various cancer types, such as small cell lung cancer and testicular cancer. Surprisingly, VP-16 (ClinicalTrials NTC04356690) was also redeveloped to treat the cytokine storm in coronavirus disease 2019 (COVID-19) in phase II in April 2020. The treatment aims at dampening the cytokine storm and is based on etoposide in the case of central nervous system. However, the initial version of PTOX was far from perfect. Almost all podophyllotoxin derivatives, including the FDA-approved drugs VP-16 and teniposide, were seriously limited in clinical therapy due to systemic toxicity, drug resistance, and low bioavailability. To meet this challenge, scientists have devoted continuous efforts to discover new candidate drugs and have developed drug strategies. This review focuses on the current clinical treatment of PTOXs and the prospective analysis for improving druggability in the rational design of new generation PTOX-derived drugs.
Author Zhao, Wei
Zhang, Youming
Li, Hong-Mei
Cong, Ying
Li, Shengying
Shen, Yuemao
Qi, Qingsheng
Tang, Ya-Jie
Li, Yue-Zhong
AuthorAffiliation State Key Laboratory of Microbial Technology
Shandong University
AuthorAffiliation_xml – name: Shandong University
– name: State Key Laboratory of Microbial Technology
Author_xml – sequence: 1
  givenname: Wei
  surname: Zhao
  fullname: Zhao, Wei
– sequence: 2
  givenname: Ying
  surname: Cong
  fullname: Cong, Ying
– sequence: 3
  givenname: Hong-Mei
  surname: Li
  fullname: Li, Hong-Mei
– sequence: 4
  givenname: Shengying
  surname: Li
  fullname: Li, Shengying
– sequence: 5
  givenname: Yuemao
  surname: Shen
  fullname: Shen, Yuemao
– sequence: 6
  givenname: Qingsheng
  surname: Qi
  fullname: Qi, Qingsheng
– sequence: 7
  givenname: Youming
  surname: Zhang
  fullname: Zhang, Youming
– sequence: 8
  givenname: Yue-Zhong
  surname: Li
  fullname: Li, Yue-Zhong
– sequence: 9
  givenname: Ya-Jie
  surname: Tang
  fullname: Tang, Ya-Jie
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32895676$$D View this record in MEDLINE/PubMed
BookMark eNqF0s9rFTEQB_AgFftavXhXAl6KsJrfu3ssz2qFoh70vGST2bcp2WRNssX337vtqxWK4Fxy-cwXZiYn6CjEAAi9pOQdJbx9b0mYCSGCjk_QhgpFKlFLdoQ2hClZEamaY3SS8zUhlNZKPUPHnDWtVLXaoLgdtfcQdpCxDhbPsUAoTns8xITdNKd448IOlxGwTctup3vnXdnjOKzWxnncex9L_OVCZSG5G7B3LmMXsNHBQMJmhCmuAUnP--fo6aB9hhf37yn68fHi-_ayuvr66fP2_KoygqtScaGN0JZSAabRTVuDAi4s1dJQrq3sOWXMGMNA9mYQoOygmOVN36tmLcNP0dkhdx3g5wK5dJPLBrzXAeKSO6YUaRsuhfg_FYK0hLXylr55RK_jksI6SMckqaWijNeren2vln4C283JTTrtuz9bX8HbAzAp5pxgeCCUdLcn7T6QL9_uTnq5YvIIG1d0cTGUpJ3_d8urQ0vK5iH67y_hvwHOyK41
CitedBy_id crossref_primary_10_1080_07391102_2022_2137241
crossref_primary_10_1002_chem_202302595
crossref_primary_10_1089_can_2023_0284
crossref_primary_10_4062_biomolther_2022_113
crossref_primary_10_1016_S1875_5364_24_60582_0
crossref_primary_10_3390_ijms25115948
crossref_primary_10_1016_j_xjidi_2024_100321
crossref_primary_10_1016_j_cej_2025_159276
crossref_primary_10_1016_j_ejphar_2021_174189
crossref_primary_10_1002_adma_202311500
crossref_primary_10_1016_j_cclet_2022_108121
crossref_primary_10_3390_molecules27155029
crossref_primary_10_1039_D1SC06719B
crossref_primary_10_2174_1570180820666230606161639
crossref_primary_10_1039_D4OB01264J
crossref_primary_10_3390_ijms23169119
crossref_primary_10_1620_tjem_2022_J069
crossref_primary_10_1002_med_21963
crossref_primary_10_1002_cbic_202200284
crossref_primary_10_4014_jmb_2109_09012
crossref_primary_10_1016_S1875_5364_24_60721_1
crossref_primary_10_1021_acs_chemrev_4c00546
crossref_primary_10_1016_j_indcrop_2025_120730
crossref_primary_10_3390_molecules29071442
crossref_primary_10_3892_ijmm_2023_5306
crossref_primary_10_1136_jnis_2023_021055
crossref_primary_10_1016_j_ajps_2024_100892
crossref_primary_10_1021_acssynbio_2c00032
crossref_primary_10_3389_fonc_2020_624954
crossref_primary_10_1016_j_eurpolymj_2024_113379
crossref_primary_10_1038_s41598_022_12093_9
crossref_primary_10_3390_biomedicines10071632
crossref_primary_10_1002_cbdv_202402375
crossref_primary_10_1016_j_ijbiomac_2024_133678
crossref_primary_10_1038_s44160_024_00564_y
crossref_primary_10_1016_j_bioorg_2022_105761
crossref_primary_10_3389_fphar_2023_1136779
crossref_primary_10_1016_j_biopha_2023_114955
crossref_primary_10_1515_ntrev_2021_0119
crossref_primary_10_26599_POM_2025_9140085
crossref_primary_10_1016_j_bcp_2022_115039
crossref_primary_10_15212_AMM_2023_0038
crossref_primary_10_1080_07391102_2022_2139766
crossref_primary_10_1038_s41598_022_26105_1
crossref_primary_10_1016_j_bmc_2023_117483
crossref_primary_10_1016_j_prmcm_2023_100353
crossref_primary_10_1021_acs_orglett_4c00096
crossref_primary_10_31857_S0023291223600463
crossref_primary_10_3390_molecules27010220
crossref_primary_10_1002_adhm_202401616
crossref_primary_10_1016_j_bioorg_2022_105906
crossref_primary_10_1016_j_bmc_2022_116815
crossref_primary_10_1016_j_apsb_2023_08_011
crossref_primary_10_1080_14786419_2024_2410410
crossref_primary_10_3390_plants12102021
crossref_primary_10_1016_j_phrs_2024_107150
crossref_primary_10_1080_10717544_2021_1995076
crossref_primary_10_1016_j_brainres_2024_149099
crossref_primary_10_1021_acs_joc_4c00036
crossref_primary_10_1016_j_ijpharm_2024_124496
crossref_primary_10_1016_j_bioorg_2024_108103
crossref_primary_10_3390_biom11040603
crossref_primary_10_3390_ph18020169
crossref_primary_10_1016_j_bmcl_2024_130031
crossref_primary_10_1002_cbic_202300035
crossref_primary_10_3390_pharmaceutics15122728
Cites_doi 10.1093/annonc/mdx009
10.1093/annonc/mdx533
10.1016/j.ejmech.2018.05.052
10.1371/journal.pone.0215886
10.1111/j.1349-7006.2011.02103.x
10.1089/cbr.2019.3298
10.1016/j.ejmech.2019.03.006
10.1200/JCO.2003.02.153
10.1080/10717544.2020.1787558
10.1016/S0140-6736(19)32222-6
10.1002/slct.201700347
10.1016/j.bioorg.2019.103384
10.1016/j.bmcl.2017.07.047
10.1093/annonc/mdx254
10.3109/10717544.2016.1141258
10.1158/0008-5472.CAN-06-0635
10.1038/sj.onc.1206948
10.1021/np50063a021
10.1126/science.1204117
10.1039/C7MD00273D
10.1016/j.ijbiomac.2016.11.053
10.1021/acs.jmedchem.9b01354
10.1016/j.taap.2011.02.006
10.1182/blood-2005-01-0293
10.1016/j.tig.2017.12.010
10.1021/tx8002356
10.1016/j.bmcl.2017.04.082
10.1016/j.jconrel.2018.07.002
10.1021/acs.jnatprod.9b01285
10.1016/j.canlet.2014.03.013
10.1016/j.bmcl.2019.02.005
10.1016/j.ejps.2013.08.016
10.1016/j.bmcl.2016.07.072
10.1038/srep34064
10.3389/fchem.2019.00434
10.1186/s12874-018-0581-z
10.3390/molecules24071424
10.2217/nnm-2016-0396
10.1042/BCJ20190736
10.1016/j.jconrel.2006.02.014
10.1158/1538-7445.AM2018-1818
10.1016/j.tiv.2016.07.018
10.1016/j.cllc.2016.10.009
10.1021/tx0600595
10.1039/C9NR01068H
10.1021/acsnano.7b07878
10.1016/j.biomaterials.2015.02.041
10.1039/C9BM00344D
10.1016/j.canlet.2004.08.011
10.1038/sj.onc.1208065
10.1016/S1470-2045(18)30349-8
10.1038/s41467-019-11570-6
10.1080/08880018.2017.1360970
10.1038/nature02393
10.1002/ajh.25091
10.1021/jm1007648
10.1016/j.biotechadv.2013.11.009
10.1016/j.msec.2019.110275
10.1007/BF00684865
10.3892/ijmm.2015.2068
10.1515/jbcpp-2018-0108
10.1093/carcin/bgt034
10.1016/j.actbio.2018.04.016
10.1016/j.colsurfb.2017.08.042
10.1016/j.bmcl.2015.11.042
10.1182/blood-2017-06-788349
10.2174/0929867324666170920161922
10.1016/j.ejmech.2018.09.022
10.1021/acsami.7b07091
10.1038/bjc.1996.231
10.1038/cddis.2016.381
10.1007/s00280-010-1315-z
10.1186/s12964-018-0263-9
10.2147/DDDT.S167382
10.1016/j.ejmech.2017.03.011
10.1021/acschembio.6b00842
10.1089/ars.2017.7086
10.1002/jps.21731
10.4155/fmc-2018-0593
10.1166/jbn.2013.1613
10.1016/j.ijpharm.2011.02.021
10.3109/10717544.2015.1048491
10.3390/pharmaceutics12030254
10.1038/sj.bjc.6602772
10.1016/S0006-2952(03)00255-7
10.1039/C9CC07883E
10.2174/1381612003398582
10.1080/14786419.2018.1474467
10.1111/cbdd.13436
10.1016/j.bmcl.2016.05.063
10.1016/j.msec.2019.03.060
10.3389/fchem.2019.00253
10.1177/095632029800900307
10.1158/1078-0432.CCR-08-1587
10.3892/or.2012.2201
10.1016/j.canlet.2020.01.008
10.1039/C9TB00651F
10.1002/9781118682784
10.1038/srep17175
10.1021/acs.molpharmaceut.8b00702
10.1002/asia.201901070
10.1111/j.1365-2141.2010.08236.x
10.1021/acs.bioconjchem.7b00165
10.1073/pnas.88.17.7654
10.1124/dmd.112.046268
10.1016/j.bmcl.2004.02.102
10.1021/tx200025y
10.1039/C8RA06360E
10.1016/j.bmcl.2018.04.019
10.1080/10717544.2020.1716875
10.3390/cells9041010
10.1007/s12032-013-0805-3
10.1158/1078-0432.MECHRES-B61
10.1158/1078-0432.CCR-16-0247
10.1016/j.biomaterials.2017.05.019
ContentType Journal Article
Copyright Copyright Royal Society of Chemistry 2021
Copyright_xml – notice: Copyright Royal Society of Chemistry 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7T7
7TM
8FD
C1K
FR3
P64
RC3
7X8
7S9
L.6
DOI 10.1039/d0np00041h
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Biotechnology Research Abstracts
Technology Research Database
Nucleic Acids Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA
MEDLINE
Genetics Abstracts
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1460-4752
EndPage 488
ExternalDocumentID 32895676
10_1039_D0NP00041H
d0np00041h
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID -
0-7
0R
123
1TJ
29M
2WC
4.4
70
705
70J
7~J
AAEMU
AAGNR
AAIWI
AANOJ
AAPBV
AAXPP
ABASK
ABDVN
ABFLS
ABGFH
ABPTK
ABRYZ
ACGFS
ACIWK
ACLDK
ACNCT
ACPRK
ADMRA
ADSRN
AENEX
AFRAH
AFVBQ
AGKEF
AGRSR
AGSTE
AGSWI
ALMA_UNASSIGNED_HOLDINGS
ANUXI
ASKNT
AUDPV
BLAPV
BSQNT
C6K
CKLOX
CS3
DU5
EBS
ECGLT
EE0
EF-
F5P
GNO
HZ
H~N
IDZ
J3I
JG
N9A
O9-
OK1
R7B
RCNCU
RIG
RNS
RPMJG
RRA
RRC
RSCEA
SKA
SLH
VH6
X
YNT
---
-~X
0R~
70~
AAHBH
AAJAE
AAMEH
AAWGC
AAXHV
AAYXX
ABEMK
ABJNI
ABPDG
ABXOH
AEFDR
AENGV
AESAV
AETIL
AFLYV
AFOGI
AFRZK
AGEGJ
AHGCF
AKMSF
APEMP
CITATION
GGIMP
H13
HZ~
R56
RAOCF
YQT
-JG
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7T7
7TM
8FD
C1K
FR3
P64
RC3
7X8
7S9
L.6
ID FETCH-LOGICAL-c436t-34ac4ad114ec8a897e6e34d1a5c13ad5b3122ccc2e5bcf4e6df62d38bb68888c3
ISSN 0265-0568
1460-4752
IngestDate Fri Jul 11 04:04:07 EDT 2025
Fri Jul 11 07:20:11 EDT 2025
Mon Jun 30 11:59:37 EDT 2025
Wed Feb 19 02:27:51 EST 2025
Thu Apr 24 22:57:06 EDT 2025
Tue Jul 01 00:53:51 EDT 2025
Fri Apr 15 11:43:17 EDT 2022
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c436t-34ac4ad114ec8a897e6e34d1a5c13ad5b3122ccc2e5bcf4e6df62d38bb68888c3
Notes Ying Cong started her doctoral study and scientific research under the supervision of Prof. Ya-Jie Tang in 2019. Her doctoral research focuses on the design, synthesis, and discovery of podophyllotoxin leading compounds with high activity and low toxicity by the strategy of specificity-targeting tumor cells or tissues.
Since 2005, Prof. Ya-Jie Tang's group has been committed to the discovery of new podophyllotoxin-derived antitumor drugs. A series of candidate drugs with nanomolar-potency antitumor activity were developed, which were superior to the approved tubulin-targeting antitumor drugs. Compared with the approved topoisomerase II-targeting anti-tumor drugs, other candidate drugs exhibited weaker DNA damage and millimolar-potency (low) toxicity. Prof. Ya-Jie Tang's group also focuses on the biomanufacture of podophyllotoxin-derived drugs in order to solve the problems of complex synthetic steps, enantiomers, environmental pollution
etc.
Associate Prof. Wei Zhao has studied and worked in Prof. Ya-Jie Tang's group to carry out research on the design, synthesis, and druggability of podophyllotoxin-derived drugs based on tubulin, topoisomerase II, or other targets for new drug development since 2007. Based on the study of the drug-tubulin complex crystal structure, a dual-target drug design strategy for podophyllotoxin derivatives was established. A method of tandem biotransformation was designed and developed to modify the molecular structure of podophyllotoxin for the directional synthesis of potential antitumor leading compounds. Wei Zhao is committed to research on druggability of podophyllotoxin derivatives.
during chemical synthesis processes.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-8342-5201
0000-0002-5244-870X
0000-0002-3881-0135
PMID 32895676
PQID 2507561237
PQPubID 2047500
PageCount 19
ParticipantIDs pubmed_primary_32895676
crossref_primary_10_1039_D0NP00041H
proquest_miscellaneous_2660983544
crossref_citationtrail_10_1039_D0NP00041H
proquest_journals_2507561237
rsc_primary_d0np00041h
proquest_miscellaneous_2440902954
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-03-01
PublicationDateYYYYMMDD 2021-03-01
PublicationDate_xml – month: 03
  year: 2021
  text: 2021-03-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Natural product reports
PublicationTitleAlternate Nat Prod Rep
PublicationYear 2021
Publisher Royal Society of Chemistry
Publisher_xml – name: Royal Society of Chemistry
References Tomasi (D0NP00041H-(cit112)/*[position()=1]) 2010; 53
Sudo (D0NP00041H-(cit13)/*[position()=1]) 1998; 9
Zhao (D0NP00041H-(cit47)/*[position()=1]) 2018; 109
Zhuo (D0NP00041H-(cit7)/*[position()=1]) 2004; 32
Messinger (D0NP00041H-(cit59)/*[position()=1]) 2017; 34
Manapov (D0NP00041H-(cit63)/*[position()=1]) 2017; 28
Schacter (D0NP00041H-(cit54)/*[position()=1]) 2009; 34
Sun (D0NP00041H-(cit99)/*[position()=1]) 2017; 27
Zhang (D0NP00041H-(cit96)/*[position()=1]) 2016; 26
Miura (D0NP00041H-(cit39)/*[position()=1]) 2011; 24
Paulsen (D0NP00041H-(cit30)/*[position()=1]) 2018; 34
Zhang (D0NP00041H-(cit81)/*[position()=1]) 2016; 26
Choudhury (D0NP00041H-(cit100)/*[position()=1]) 2020; 106
Mo (D0NP00041H-(cit127)/*[position()=1]) 2011; 409
Zhao (D0NP00041H-(cit52)/*[position()=1]) 2013; 50
Alliot (D0NP00041H-(cit109)/*[position()=1]) 2019; 11
Gerber (D0NP00041H-(cit64)/*[position()=1]) 2017; 18
Lou (D0NP00041H-(cit2)/*[position()=1]) 2018; 25
Brantley-Finley (D0NP00041H-(cit33)/*[position()=1]) 2003; 66
Xu (D0NP00041H-(cit8)/*[position()=1]) 2019; 33
Shi (D0NP00041H-(cit124)/*[position()=1]) 2020; 33
Elizabeth (D0NP00041H-(cit50)/*[position()=1]) 2016; 22
Linder (D0NP00041H-(cit23)/*[position()=1]) 2007; 67
Lee (D0NP00041H-(cit34)/*[position()=1]) 2016; 36
Gunduz (D0NP00041H-(cit38)/*[position()=1]) 2012; 40
Ahmed (D0NP00041H-(cit57)/*[position()=1]) 2000; 83
Zhang (D0NP00041H-(cit95)/*[position()=1]) 2017; 131
Shin (D0NP00041H-(cit32)/*[position()=1]) 2016; 6
Vishnuvardhan (D0NP00041H-(cit91)/*[position()=1]) 2017; 8
Zhao (D0NP00041H-(cit73)/*[position()=1]) 2019; 170
Czyz (D0NP00041H-(cit60)/*[position()=1]) 2018; 93
Duan (D0NP00041H-(cit62)/*[position()=1]) 2017; 159
Chen (D0NP00041H-(cit82)/*[position()=1]) 2012; 103
Wang (D0NP00041H-(cit84)/*[position()=1]) 2018; 16
Zhao (D0NP00041H-(cit79)/*[position()=1]) 2015; 5
Lan (D0NP00041H-(cit67)/*[position()=1]) 2018; 19
Montero-Baladía (D0NP00041H-(cit18)/*[position()=1]) 2020; 81
Ozols (D0NP00041H-(cit66)/*[position()=1]) 2003; 21
Paz-Ares (D0NP00041H-(cit3)/*[position()=1]) 2019; 394
Li (D0NP00041H-(cit89)/*[position()=1]) 2019; 14
Zhang (D0NP00041H-(cit41)/*[position()=1]) 2011; 252
Conlon (D0NP00041H-(cit14)/*[position()=1]) 2020; 35
Zi (D0NP00041H-(cit114)/*[position()=1]) 2019; 7
Rigiracciolo (D0NP00041H-(cit24)/*[position()=1]) 2020; 9
Ravelli (D0NP00041H-(cit71)/*[position()=1]) 2004; 428
Han (D0NP00041H-(cit78)/*[position()=1]) 2016; 26
Bi (D0NP00041H-(cit16)/*[position()=1]) 2017; 28
Fields (D0NP00041H-(cit55)/*[position()=1]) 1995; 1
Ahmad (D0NP00041H-(cit120)/*[position()=1]) 2019; 100
Rebbaa (D0NP00041H-(cit43)/*[position()=1]) 2005; 219
Hou (D0NP00041H-(cit116)/*[position()=1]) 2019; 14
Kang (D0NP00041H-(cit40)/*[position()=1]) 2009; 22
Yavuz (D0NP00041H-(cit125)/*[position()=1]) 2018; 285
Uchino (D0NP00041H-(cit103)/*[position()=1]) 2005; 93
Liu (D0NP00041H-(cit111)/*[position()=1]) 2017; 9
Burke (D0NP00041H-(cit87)/*[position()=1]) 2013; 34
Chen (D0NP00041H-(cit117)/*[position()=1]) 2017; 95
Nerella (D0NP00041H-(cit72)/*[position()=1]) 2020; 94
Wei (D0NP00041H-(cit85)/*[position()=1]) 2019; 7
Liang (D0NP00041H-(cit65)/*[position()=1]) 2017; 28
Zhang (D0NP00041H-(cit97)/*[position()=1]) 2018; 158
Zhao (D0NP00041H-(cit19)/*[position()=1]) 2017; 12
Menu (D0NP00041H-(cit28)/*[position()=1]) 2006; 107
Zi (D0NP00041H-(cit22)/*[position()=1]) 2017; 2
Li (D0NP00041H-(cit115)/*[position()=1]) 2019; 7
Calvo-Flores (D0NP00041H-(cit9)/*[position()=1]) 2015
Wu (D0NP00041H-(cit42)/*[position()=1]) 2014; 347
Pinto (D0NP00041H-(cit69)/*[position()=1]) 2011; 67
Patnaik (D0NP00041H-(cit121)/*[position()=1]) 2019; 30
Zu (D0NP00041H-(cit105)/*[position()=1]) 2020; 27
Roy (D0NP00041H-(cit108)/*[position()=1]) 2017; 137
Liu (D0NP00041H-(cit11)/*[position()=1]) 2014
Huang (D0NP00041H-(cit128)/*[position()=1]) 2020; 12
Seebacher (D0NP00041H-(cit45)/*[position()=1]) 2016; 7
Akhtar (D0NP00041H-(cit53)/*[position()=1]) 2013; 9
Roy (D0NP00041H-(cit106)/*[position()=1]) 2015; 52
Jiang (D0NP00041H-(cit118)/*[position()=1]) 2015; 23
Wu (D0NP00041H-(cit86)/*[position()=1]) 2018; 155
Han (D0NP00041H-(cit83)/*[position()=1]) 2004; 14
Zhang (D0NP00041H-(cit88)/*[position()=1]) 2018; 8
Yano (D0NP00041H-(cit5)/*[position()=1]) 2009; 98
Wu (D0NP00041H-(cit21)/*[position()=1]) 2011; 333
Abad (D0NP00041H-(cit49)/*[position()=1]) 2020; 474
Wen (D0NP00041H-(cit110)/*[position()=1]) 2019; 29
Barker (D0NP00041H-(cit10)/*[position()=1]) 2019; 24
Bergsten (D0NP00041H-(cit68)/*[position()=1]) 2017; 130
Fong (D0NP00041H-(cit27)/*[position()=1]) 2012; 18
Zi (D0NP00041H-(cit90)/*[position()=1]) 2018; 12
Zhou (D0NP00041H-(cit104)/*[position()=1]) 2018; 73
Zhang (D0NP00041H-(cit119)/*[position()=1]) 2016; 23
Commander (D0NP00041H-(cit58)/*[position()=1]) 2010; 150
Ambudkar (D0NP00041H-(cit44)/*[position()=1]) 2003; 22
Wan (D0NP00041H-(cit126)/*[position()=1]) 2018; 12
Gao (D0NP00041H-(cit123)/*[position()=1]) 2018; 17
Newman (D0NP00041H-(cit1)/*[position()=1]) 2020; 83
Asimina (D0NP00041H-(cit31)/*[position()=1]) 2018; 29
Wang (D0NP00041H-(cit75)/*[position()=1]) 2018; 28
Cao (D0NP00041H-(cit74)/*[position()=1]) 2015; 35
Bugg (D0NP00041H-(cit4)/*[position()=1]) 1991; 88
Ou (D0NP00041H-(cit102)/*[position()=1]) 2019; 7
Yang (D0NP00041H-(cit37)/*[position()=1]) 2013; 29
van Hoppe (D0NP00041H-(cit46)/*[position()=1]) 2018; 15
Lusvarghi (D0NP00041H-(cit48)/*[position()=1]) 2019; 476
Alliot (D0NP00041H-(cit113)/*[position()=1]) 2019; 55
Ling (D0NP00041H-(cit122)/*[position()=1]) 2017; 12
Lamprecht (D0NP00041H-(cit61)/*[position()=1]) 2006; 112
Yang (D0NP00041H-(cit107)/*[position()=1]) 2017; 28
Wu (D0NP00041H-(cit129)/*[position()=1]) 2020; 27
Shiozawa (D0NP00041H-(cit70)/*[position()=1]) 2009; 15
Manapov (D0NP00041H-(cit17)/*[position()=1]) 2017; 28
Gordaliza (D0NP00041H-(cit80)/*[position()=1]) 2000; 6
Li (D0NP00041H-(cit25)/*[position()=1]) 2018; 78
Young (D0NP00041H-(cit56)/*[position()=1]) 1995; 86
Singh (D0NP00041H-(cit26)/*[position()=1]) 2014; 31
Xu (D0NP00041H-(cit77)/*[position()=1]) 2017; 27
Cheng (D0NP00041H-(cit98)/*[position()=1]) 2020; 63
Vasilcanu (D0NP00041H-(cit29)/*[position()=1]) 2004; 23
Haim (D0NP00041H-(cit36)/*[position()=1]) 1987; 47
Liu (D0NP00041H-(cit101)/*[position()=1]) 2014; 32
Yasuhiro (D0NP00041H-(cit15)/*[position()=1]) 2020; 111
Hou (D0NP00041H-(cit93)/*[position()=1]) 2019; 93
Lee (D0NP00041H-(cit20)/*[position()=1]) 1989; 52
Fan (D0NP00041H-(cit35)/*[position()=1]) 2006; 19
Broderick (D0NP00041H-(cit51)/*[position()=1]) 2019; 10
Cao (D0NP00041H-(cit76)/*[position()=1]) 2018; 17
Lu (D0NP00041H-(cit94)/*[position()=1]) 2019; 11
Vassetzky (D0NP00041H-(cit6)/*[position()=1]) 1996; 73
Murray (D0NP00041H-(cit12)/*[position()=1]) 2018; 18
Zi (D0NP00041H-(cit92)/*[position()=1]) 2017; 2
References_xml – issn: 2015
  publication-title: Lignin and Lignans as Renewable Raw Materials
  doi: Calvo-Flores Dobado Isac-García Martin-Martinez
– volume: 28
  start-page: 777
  year: 2017
  ident: D0NP00041H-(cit65)/*[position()=1]
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx009
– volume: 28
  start-page: 3101
  year: 2017
  ident: D0NP00041H-(cit16)/*[position()=1]
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx533
– volume: 155
  start-page: 183
  year: 2018
  ident: D0NP00041H-(cit86)/*[position()=1]
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2018.05.052
– volume: 14
  start-page: e0215886
  year: 2019
  ident: D0NP00041H-(cit89)/*[position()=1]
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0215886
– volume: 103
  start-page: 80
  year: 2012
  ident: D0NP00041H-(cit82)/*[position()=1]
  publication-title: Cancer Sci.
  doi: 10.1111/j.1349-7006.2011.02103.x
– volume: 35
  start-page: 249
  year: 2020
  ident: D0NP00041H-(cit14)/*[position()=1]
  publication-title: Cancer Biother.Radiopharm.
  doi: 10.1089/cbr.2019.3298
– volume: 33
  start-page: 13245
  year: 2020
  ident: D0NP00041H-(cit124)/*[position()=1]
  publication-title: Dermatol. Ther.
– volume: 170
  start-page: 73
  year: 2019
  ident: D0NP00041H-(cit73)/*[position()=1]
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2019.03.006
– volume: 21
  start-page: 3194
  year: 2003
  ident: D0NP00041H-(cit66)/*[position()=1]
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2003.02.153
– volume: 81
  start-page: 452
  year: 2020
  ident: D0NP00041H-(cit18)/*[position()=1]
  publication-title: J. Infect.
– volume: 27
  start-page: 974
  year: 2020
  ident: D0NP00041H-(cit129)/*[position()=1]
  publication-title: Drug Delivery
  doi: 10.1080/10717544.2020.1787558
– volume: 394
  start-page: 1929
  year: 2019
  ident: D0NP00041H-(cit3)/*[position()=1]
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)32222-6
– volume: 2
  start-page: 5038
  year: 2017
  ident: D0NP00041H-(cit22)/*[position()=1]
  publication-title: ChemistrySelect
  doi: 10.1002/slct.201700347
– volume: 94
  start-page: 103384
  year: 2020
  ident: D0NP00041H-(cit72)/*[position()=1]
  publication-title: Bioorg. Chem.
  doi: 10.1016/j.bioorg.2019.103384
– volume: 27
  start-page: 4066
  year: 2017
  ident: D0NP00041H-(cit99)/*[position()=1]
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2017.07.047
– volume: 28
  start-page: 2319
  year: 2017
  ident: D0NP00041H-(cit17)/*[position()=1]
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx254
– volume: 23
  start-page: 1838
  year: 2016
  ident: D0NP00041H-(cit119)/*[position()=1]
  publication-title: Drug Delivery
  doi: 10.3109/10717544.2016.1141258
– volume: 67
  start-page: 2899
  year: 2007
  ident: D0NP00041H-(cit23)/*[position()=1]
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-0635
– volume: 22
  start-page: 7468
  year: 2003
  ident: D0NP00041H-(cit44)/*[position()=1]
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206948
– volume: 52
  start-page: 606
  year: 1989
  ident: D0NP00041H-(cit20)/*[position()=1]
  publication-title: J. Nat. Prod.
  doi: 10.1021/np50063a021
– volume: 333
  start-page: 459
  year: 2011
  ident: D0NP00041H-(cit21)/*[position()=1]
  publication-title: Science
  doi: 10.1126/science.1204117
– volume: 8
  start-page: 1817
  year: 2017
  ident: D0NP00041H-(cit91)/*[position()=1]
  publication-title: Medchemcomm
  doi: 10.1039/C7MD00273D
– volume: 95
  start-page: 451
  year: 2017
  ident: D0NP00041H-(cit117)/*[position()=1]
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2016.11.053
– volume: 63
  start-page: 2877
  year: 2020
  ident: D0NP00041H-(cit98)/*[position()=1]
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.9b01354
– volume: 252
  start-page: 62
  year: 2011
  ident: D0NP00041H-(cit41)/*[position()=1]
  publication-title: Toxicol. Appl. Pharmacol.
  doi: 10.1016/j.taap.2011.02.006
– volume: 86
  start-page: 3885
  year: 1995
  ident: D0NP00041H-(cit56)/*[position()=1]
  publication-title: Blood
– volume: 107
  start-page: 655
  year: 2006
  ident: D0NP00041H-(cit28)/*[position()=1]
  publication-title: Blood
  doi: 10.1182/blood-2005-01-0293
– volume: 34
  start-page: 270
  year: 2018
  ident: D0NP00041H-(cit30)/*[position()=1]
  publication-title: Trends Genet.
  doi: 10.1016/j.tig.2017.12.010
– volume: 22
  start-page: 106
  year: 2009
  ident: D0NP00041H-(cit40)/*[position()=1]
  publication-title: Chem. Res. Toxicol.
  doi: 10.1021/tx8002356
– volume: 27
  start-page: 2890
  year: 2017
  ident: D0NP00041H-(cit77)/*[position()=1]
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2017.04.082
– volume: 285
  start-page: 162
  year: 2018
  ident: D0NP00041H-(cit125)/*[position()=1]
  publication-title: J. Controlled Release
  doi: 10.1016/j.jconrel.2018.07.002
– volume: 83
  start-page: 770
  year: 2020
  ident: D0NP00041H-(cit1)/*[position()=1]
  publication-title: J. Nat. Prod.
  doi: 10.1021/acs.jnatprod.9b01285
– volume: 347
  start-page: 159
  year: 2014
  ident: D0NP00041H-(cit42)/*[position()=1]
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2014.03.013
– volume: 29
  start-page: 1019
  year: 2019
  ident: D0NP00041H-(cit110)/*[position()=1]
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2019.02.005
– volume: 50
  start-page: 429
  year: 2013
  ident: D0NP00041H-(cit52)/*[position()=1]
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2013.08.016
– volume: 2
  start-page: 5038
  year: 2017
  ident: D0NP00041H-(cit92)/*[position()=1]
  publication-title: ChemistrySelect
  doi: 10.1002/slct.201700347
– volume: 26
  start-page: 4466
  year: 2016
  ident: D0NP00041H-(cit81)/*[position()=1]
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2016.07.072
– volume: 6
  start-page: 34064
  year: 2016
  ident: D0NP00041H-(cit32)/*[position()=1]
  publication-title: Sci. Rep.
  doi: 10.1038/srep34064
– volume: 7
  start-page: 434
  year: 2019
  ident: D0NP00041H-(cit114)/*[position()=1]
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2019.00434
– volume: 18
  start-page: 125
  year: 2018
  ident: D0NP00041H-(cit12)/*[position()=1]
  publication-title: BMC Med. Res. Methodol.
  doi: 10.1186/s12874-018-0581-z
– volume: 24
  start-page: 1424
  year: 2019
  ident: D0NP00041H-(cit10)/*[position()=1]
  publication-title: Molecules
  doi: 10.3390/molecules24071424
– volume: 12
  start-page: 657
  year: 2017
  ident: D0NP00041H-(cit122)/*[position()=1]
  publication-title: Nanomedicine
  doi: 10.2217/nnm-2016-0396
– volume: 476
  start-page: 3737
  year: 2019
  ident: D0NP00041H-(cit48)/*[position()=1]
  publication-title: Biochem. J.
  doi: 10.1042/BCJ20190736
– volume: 83
  start-page: 79
  year: 2000
  ident: D0NP00041H-(cit57)/*[position()=1]
  publication-title: Br. J. Cancer
– volume: 112
  start-page: 208
  year: 2006
  ident: D0NP00041H-(cit61)/*[position()=1]
  publication-title: J. Controlled Release
  doi: 10.1016/j.jconrel.2006.02.014
– volume: 78
  start-page: 1818
  year: 2018
  ident: D0NP00041H-(cit25)/*[position()=1]
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.AM2018-1818
– volume: 36
  start-page: 142
  year: 2016
  ident: D0NP00041H-(cit34)/*[position()=1]
  publication-title: Toxicol. in Vitro
  doi: 10.1016/j.tiv.2016.07.018
– volume: 18
  start-page: 333
  year: 2017
  ident: D0NP00041H-(cit64)/*[position()=1]
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2016.10.009
– volume: 19
  start-page: 937
  year: 2006
  ident: D0NP00041H-(cit35)/*[position()=1]
  publication-title: Chem. Res. Toxicol.
  doi: 10.1021/tx0600595
– volume: 11
  start-page: 9756
  year: 2019
  ident: D0NP00041H-(cit109)/*[position()=1]
  publication-title: Nanoscale
  doi: 10.1039/C9NR01068H
– volume: 12
  start-page: 2426
  year: 2018
  ident: D0NP00041H-(cit126)/*[position()=1]
  publication-title: ACS Nano
  doi: 10.1021/acsnano.7b07878
– volume: 17
  start-page: 474
  year: 2018
  ident: D0NP00041H-(cit76)/*[position()=1]
  publication-title: Mol. Med. Rep.
– volume: 52
  start-page: 335
  year: 2015
  ident: D0NP00041H-(cit106)/*[position()=1]
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2015.02.041
– volume: 7
  start-page: 2491
  year: 2019
  ident: D0NP00041H-(cit102)/*[position()=1]
  publication-title: Biomater. Sci.
  doi: 10.1039/C9BM00344D
– volume: 219
  start-page: 1
  year: 2005
  ident: D0NP00041H-(cit43)/*[position()=1]
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2004.08.011
– volume: 23
  start-page: 7854
  year: 2004
  ident: D0NP00041H-(cit29)/*[position()=1]
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1208065
– volume: 19
  start-page: 1239
  year: 2018
  ident: D0NP00041H-(cit67)/*[position()=1]
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30349-8
– volume: 10
  start-page: 3644
  year: 2019
  ident: D0NP00041H-(cit51)/*[position()=1]
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-11570-6
– volume: 34
  start-page: 187
  year: 2017
  ident: D0NP00041H-(cit59)/*[position()=1]
  publication-title: Pediatr. Hematol. Oncol.
  doi: 10.1080/08880018.2017.1360970
– volume: 47
  start-page: 5835
  year: 1987
  ident: D0NP00041H-(cit36)/*[position()=1]
  publication-title: Cancer Res.
– volume: 428
  start-page: 198
  year: 2004
  ident: D0NP00041H-(cit71)/*[position()=1]
  publication-title: Nature
  doi: 10.1038/nature02393
– volume: 93
  start-page: 778
  year: 2018
  ident: D0NP00041H-(cit60)/*[position()=1]
  publication-title: Am. J. Hematol.
  doi: 10.1002/ajh.25091
– volume: 53
  start-page: 7647
  year: 2010
  ident: D0NP00041H-(cit112)/*[position()=1]
  publication-title: J. Med. Chem.
  doi: 10.1021/jm1007648
– volume: 32
  start-page: 693
  year: 2014
  ident: D0NP00041H-(cit101)/*[position()=1]
  publication-title: Biotechnol. Adv.
  doi: 10.1016/j.biotechadv.2013.11.009
– volume: 106
  start-page: 110275
  year: 2020
  ident: D0NP00041H-(cit100)/*[position()=1]
  publication-title: Mater. Sci. Eng., C
  doi: 10.1016/j.msec.2019.110275
– volume: 34
  start-page: S58
  year: 2009
  ident: D0NP00041H-(cit54)/*[position()=1]
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/BF00684865
– volume: 35
  start-page: 771
  year: 2015
  ident: D0NP00041H-(cit74)/*[position()=1]
  publication-title: Int. J. Mol. Med.
  doi: 10.3892/ijmm.2015.2068
– volume: 30
  start-page: 1
  issue: 5
  year: 2019
  ident: D0NP00041H-(cit121)/*[position()=1]
  publication-title: J. Basic. Clin. Physiol. Pharmacol.
  doi: 10.1515/jbcpp-2018-0108
– volume: 34
  start-page: 503
  year: 2013
  ident: D0NP00041H-(cit87)/*[position()=1]
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgt034
– volume: 73
  start-page: 388
  year: 2018
  ident: D0NP00041H-(cit104)/*[position()=1]
  publication-title: Acta Biomater.
  doi: 10.1016/j.actbio.2018.04.016
– volume: 159
  start-page: 880
  year: 2017
  ident: D0NP00041H-(cit62)/*[position()=1]
  publication-title: Colloids Surf., B
  doi: 10.1016/j.colsurfb.2017.08.042
– volume: 26
  start-page: 38
  year: 2016
  ident: D0NP00041H-(cit96)/*[position()=1]
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2015.11.042
– volume: 130
  start-page: 2728
  year: 2017
  ident: D0NP00041H-(cit68)/*[position()=1]
  publication-title: Blood
  doi: 10.1182/blood-2017-06-788349
– volume: 25
  start-page: 5128
  year: 2018
  ident: D0NP00041H-(cit2)/*[position()=1]
  publication-title: Curr. Med. Chem.
  doi: 10.2174/0929867324666170920161922
– volume: 158
  start-page: 951
  year: 2018
  ident: D0NP00041H-(cit97)/*[position()=1]
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2018.09.022
– volume: 9
  start-page: 29496
  year: 2017
  ident: D0NP00041H-(cit111)/*[position()=1]
  publication-title: ACS Appl. Mater. Interfaces
  doi: 10.1021/acsami.7b07091
– volume: 17
  start-page: 6506
  year: 2018
  ident: D0NP00041H-(cit123)/*[position()=1]
  publication-title: Mol. Med. Rep.
– volume: 73
  start-page: 1201
  year: 1996
  ident: D0NP00041H-(cit6)/*[position()=1]
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.1996.231
– volume: 7
  start-page: e2510
  year: 2016
  ident: D0NP00041H-(cit45)/*[position()=1]
  publication-title: Cell Death Dis.
  doi: 10.1038/cddis.2016.381
– volume: 67
  start-page: 275
  year: 2011
  ident: D0NP00041H-(cit69)/*[position()=1]
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-010-1315-z
– volume: 16
  start-page: 52
  year: 2018
  ident: D0NP00041H-(cit84)/*[position()=1]
  publication-title: Cell Commun. Signaling
  doi: 10.1186/s12964-018-0263-9
– volume: 28
  start-page: 2319
  year: 2017
  ident: D0NP00041H-(cit63)/*[position()=1]
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx254
– volume: 12
  start-page: 3393
  year: 2018
  ident: D0NP00041H-(cit90)/*[position()=1]
  publication-title: Drug Des., Dev. Ther.
  doi: 10.2147/DDDT.S167382
– volume: 131
  start-page: 81
  year: 2017
  ident: D0NP00041H-(cit95)/*[position()=1]
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2017.03.011
– volume: 111
  start-page: 877
  year: 2020
  ident: D0NP00041H-(cit15)/*[position()=1]
  publication-title: Clin. Lymphoma, Myeloma Leuk.
– volume: 12
  start-page: 746
  year: 2017
  ident: D0NP00041H-(cit19)/*[position()=1]
  publication-title: ACS Chem. Biol.
  doi: 10.1021/acschembio.6b00842
– volume: 29
  start-page: 1633
  year: 2018
  ident: D0NP00041H-(cit31)/*[position()=1]
  publication-title: Antioxid. Redox Signaling
  doi: 10.1089/ars.2017.7086
– volume: 98
  start-page: 4402
  year: 2009
  ident: D0NP00041H-(cit5)/*[position()=1]
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.21731
– volume: 11
  start-page: 3015
  year: 2019
  ident: D0NP00041H-(cit94)/*[position()=1]
  publication-title: Future Med. Chem.
  doi: 10.4155/fmc-2018-0593
– volume: 9
  start-page: 1216
  year: 2013
  ident: D0NP00041H-(cit53)/*[position()=1]
  publication-title: J. Biomed. Nanotechnol.
  doi: 10.1166/jbn.2013.1613
– start-page: 1
  year: 2014
  ident: D0NP00041H-(cit11)/*[position()=1]
  publication-title: Med. Res. Rev.
– volume: 409
  start-page: 38
  year: 2011
  ident: D0NP00041H-(cit127)/*[position()=1]
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2011.02.021
– volume: 23
  start-page: 1379
  year: 2015
  ident: D0NP00041H-(cit118)/*[position()=1]
  publication-title: Drug Delivery
  doi: 10.3109/10717544.2015.1048491
– volume: 12
  start-page: 254
  year: 2020
  ident: D0NP00041H-(cit128)/*[position()=1]
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12030254
– volume: 93
  start-page: 678
  year: 2005
  ident: D0NP00041H-(cit103)/*[position()=1]
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6602772
– volume: 66
  start-page: 459
  year: 2003
  ident: D0NP00041H-(cit33)/*[position()=1]
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/S0006-2952(03)00255-7
– volume: 55
  start-page: 14968
  year: 2019
  ident: D0NP00041H-(cit113)/*[position()=1]
  publication-title: Chem. Commun.
  doi: 10.1039/C9CC07883E
– volume: 6
  start-page: 1811
  year: 2000
  ident: D0NP00041H-(cit80)/*[position()=1]
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/1381612003398582
– volume: 33
  start-page: 1357
  year: 2019
  ident: D0NP00041H-(cit8)/*[position()=1]
  publication-title: Nat. Prod. Res.
  doi: 10.1080/14786419.2018.1474467
– volume: 32
  start-page: 993
  year: 2004
  ident: D0NP00041H-(cit7)/*[position()=1]
  publication-title: Drug Metab. Dispos.
– volume: 1
  start-page: 105
  year: 1995
  ident: D0NP00041H-(cit55)/*[position()=1]
  publication-title: Clin. Cancer Res.
– volume: 93
  start-page: 473
  year: 2019
  ident: D0NP00041H-(cit93)/*[position()=1]
  publication-title: Chem. Biol. Drug Des.
  doi: 10.1111/cbdd.13436
– volume: 26
  start-page: 3237
  year: 2016
  ident: D0NP00041H-(cit78)/*[position()=1]
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2016.05.063
– volume: 100
  start-page: 959
  year: 2019
  ident: D0NP00041H-(cit120)/*[position()=1]
  publication-title: Mater. Sci. Eng., C
  doi: 10.1016/j.msec.2019.03.060
– volume: 7
  start-page: 253
  year: 2019
  ident: D0NP00041H-(cit85)/*[position()=1]
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2019.00253
– volume: 9
  start-page: 263
  year: 1998
  ident: D0NP00041H-(cit13)/*[position()=1]
  publication-title: Antiviral Chem. Chemother.
  doi: 10.1177/095632029800900307
– volume: 15
  start-page: 1698
  year: 2009
  ident: D0NP00041H-(cit70)/*[position()=1]
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-08-1587
– volume: 29
  start-page: 1215
  year: 2013
  ident: D0NP00041H-(cit37)/*[position()=1]
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2012.2201
– volume: 474
  start-page: 106
  year: 2020
  ident: D0NP00041H-(cit49)/*[position()=1]
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2020.01.008
– volume: 7
  start-page: 5814
  year: 2019
  ident: D0NP00041H-(cit115)/*[position()=1]
  publication-title: J. Mater. Chem. B
  doi: 10.1039/C9TB00651F
– volume-title: Lignin and Lignans as Renewable Raw Materials
  year: 2015
  ident: D0NP00041H-(cit9)/*[position()=1]
  doi: 10.1002/9781118682784
– volume: 5
  start-page: 17175
  year: 2015
  ident: D0NP00041H-(cit79)/*[position()=1]
  publication-title: Sci. Rep.
  doi: 10.1038/srep17175
– volume: 15
  start-page: 5124
  year: 2018
  ident: D0NP00041H-(cit46)/*[position()=1]
  publication-title: Mol. Pharm.
  doi: 10.1021/acs.molpharmaceut.8b00702
– volume: 14
  start-page: 3840
  year: 2019
  ident: D0NP00041H-(cit116)/*[position()=1]
  publication-title: Chem.–Asian J.
  doi: 10.1002/asia.201901070
– volume: 109
  start-page: 224
  year: 2018
  ident: D0NP00041H-(cit47)/*[position()=1]
  publication-title: Cancer Sci.
– volume: 150
  start-page: 345
  year: 2010
  ident: D0NP00041H-(cit58)/*[position()=1]
  publication-title: Br. J. Haematol.
  doi: 10.1111/j.1365-2141.2010.08236.x
– volume: 28
  start-page: 1505
  year: 2017
  ident: D0NP00041H-(cit107)/*[position()=1]
  publication-title: Bioconjugate Chem.
  doi: 10.1021/acs.bioconjchem.7b00165
– volume: 88
  start-page: 7654
  year: 1991
  ident: D0NP00041H-(cit4)/*[position()=1]
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.88.17.7654
– volume: 40
  start-page: 2074
  year: 2012
  ident: D0NP00041H-(cit38)/*[position()=1]
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.112.046268
– volume: 14
  start-page: 2979
  year: 2004
  ident: D0NP00041H-(cit83)/*[position()=1]
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2004.02.102
– volume: 24
  start-page: 1836
  year: 2011
  ident: D0NP00041H-(cit39)/*[position()=1]
  publication-title: Chem. Res. Toxicol.
  doi: 10.1021/tx200025y
– volume: 8
  start-page: 34266
  year: 2018
  ident: D0NP00041H-(cit88)/*[position()=1]
  publication-title: RSC Adv.
  doi: 10.1039/C8RA06360E
– volume: 28
  start-page: 1817
  year: 2018
  ident: D0NP00041H-(cit75)/*[position()=1]
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2018.04.019
– volume: 27
  start-page: 248
  year: 2020
  ident: D0NP00041H-(cit105)/*[position()=1]
  publication-title: Drug Delivery
  doi: 10.1080/10717544.2020.1716875
– volume: 9
  start-page: 1010
  year: 2020
  ident: D0NP00041H-(cit24)/*[position()=1]
  publication-title: Cell
  doi: 10.3390/cells9041010
– volume: 31
  start-page: 805
  year: 2014
  ident: D0NP00041H-(cit26)/*[position()=1]
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-013-0805-3
– volume: 18
  start-page: B61
  year: 2012
  ident: D0NP00041H-(cit27)/*[position()=1]
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.MECHRES-B61
– volume: 22
  start-page: 5651
  year: 2016
  ident: D0NP00041H-(cit50)/*[position()=1]
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-0247
– volume: 137
  start-page: 11
  year: 2017
  ident: D0NP00041H-(cit108)/*[position()=1]
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2017.05.019
SSID ssj0011766
Score 2.5897963
SecondaryResourceType review_article
Snippet Covering: up to 2020 As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX)...
Covering: up to 2020As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX)...
As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum...
SourceID proquest
pubmed
crossref
rsc
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 47
SubjectTerms Anticancer properties
antineoplastic activity
Antineoplastic Agents - therapeutic use
Antitumor activity
bioactive compounds
Bioavailability
Biocompatibility
Cancer therapies
cancer therapy
Cell cycle
Central nervous system
Chemotherapy
Coronaviruses
COVID-19
COVID-19 infection
Cytokine storm
Cytokines
Deoxyribonucleic acid
DNA
DNA damage
DNA topoisomerase (ATP-hydrolysing)
Drug Design
Drug development
Drug resistance
drug therapy
Drugs
Etoposide
Growth factors
Health services
Herbal medicine
herbal medicines
Humans
Insulin
insulin-like growth factor I receptor
Lung cancer
lung neoplasms
Neoplasms - drug therapy
Podophyllotoxin
Podophyllotoxin - therapeutic use
Podophyllum
RNA
Small cell lung carcinoma
Teniposide
testes
Testicular cancer
Toxicity
Tubulin
Viral diseases
Title Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy
URI https://www.ncbi.nlm.nih.gov/pubmed/32895676
https://www.proquest.com/docview/2507561237
https://www.proquest.com/docview/2440902954
https://www.proquest.com/docview/2660983544
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLegO8AF8TVWGMgILmjKSGzHSY5T6VRQKUi0opyi-KNbpZJEXYqAv57n2ElaNtCgh6iynyzH7xf7Pb8vhF6CyBEIDZoqHHW-xzSlngh86YHooYJIJHyR1dk-J3w0Y-_m4fy36JJKHMufV8aV_A9XoQ34aqJk_4Gz7aDQAP-Bv_AEDsPzWjweNJVQbKLlsqiM748NSTTxj-66wMiWar05O7M5uWubegnqKKzwalVUxfdl7imY7zcQPg1d7SIrDRzWR8DTry5Ia8cAPMlswo7SZoxtbA9b99D1HexnvWytHM7590tzWBo3IFszG3q89x2lbf10Dm_2oyF2FxNkyzPL7aXMcD8KdzZbGm-Bih6VxywCIlvZz-2hzFYSccex67u00_vUJEpVfl4asTQ4786zxoY_-ZCezsbjdDqcT2-iPQJ6BOmhvZPh9O24NTSZ_Jg2AM3OtclgS5PX3di7MsslRQTEknVTLqYWS6Z30R2nT-ATC4576IbO76Nbg6aM3wNUdCDBABLcggQDSHALEgw8xtsgwcUC_wEkNd0FXubYggRvg-Qhmp0Op4OR56pseJJRXnmUZZJlCvRiLeMsTiLNNWUqyEIZ0EyFggaESCmJDoVcMM3VghNFYyF4DD9J91EvL3J9gHCoArWgkoiQREwqEsM6Cp5IrbIsIbHfR6-adUylS0FvKqGs0toVgibpG3_ysV7zUR-9aGlLm3jlSqrDhh2p-zAvUpDqI1P0lUZ99LzthmU3trAs18UGaBgzHslJyP5Cw7mfmItRoHlkWd1OhZI4CXnE-2gfeN82d5h5fI1hn6Db3YdziHrVeqOfgoxbiWcOp78Avn6suw
linkProvider Royal Society of Chemistry
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Challenges+and+potential+for+improving+the+druggability+of+podophyllotoxin-derived+drugs+in+cancer+chemotherapy&rft.jtitle=Natural+product+reports&rft.au=Zhao%2C+Wei&rft.au=Cong%2C+Ying&rft.au=Li%2C+Hong-Mei&rft.au=Li%2C+Shengying&rft.date=2021-03-01&rft.issn=1460-4752&rft.volume=38&rft.issue=3+p.470-488&rft.spage=470&rft.epage=488&rft_id=info:doi/10.1039%2Fd0np00041h&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0265-0568&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0265-0568&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0265-0568&client=summon